Omeros Corporation (OMER)
OMER moved a median of +0.49% 30 minutes after news, and +0.91% by the close. How OMER actually reacts to news — the realized, point-in-time move the market made, measured across 232 labeled events over the last three years with zero look-ahead.
OMER’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 231 |
| 30-min | +0.49% | 57% | 231 |
| 60-min | +0.32% | 57% | 232 |
| to close | +0.91% | 63% | 230 |
| Middle 50% of OMER reactions | -0.86% to +2.90% |
|---|---|
| Median reaction (30-min) | +0.49% |
| Measured reactions | 232 |
Half of all Omeros Corporation news events land between -0.86% and +2.90% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How OMER reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 18 | +0.58% | 67% | +0.25% |
| Analyst downgrades | 17 | -0.57% | 35% | -1.71% |
| Rating reiterations | 69 | +0.49% | 58% | +0.32% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how OMER ranks against every other measured name →
That’s how OMER usually reacts — get an email when it moves on news →Email me when OMER moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to OMER's baseline. Nothing else.
Recent OMER events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA | Press release | Business Wire | -5.74% | -9.70% | |
| Form 8-K OMEROS CORP For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -4.32% | -1.77% | |
| Form S-8 OMEROS CORP | SEC filing · Form S-8 | SEC EDGAR | -4.32% | -1.77% | |
| Form 10-Q OMEROS CORP For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +7.19% | +4.77% | |
| Form 8-K OMEROS CORP For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +7.19% | +4.77% | |
| Omeros Corporation Reports Second Quarter 2026 Financial Results | Press release | Business Wire | +7.19% | +4.77% | |
| Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026 | Press release | Business Wire | -1.95% | — | |
| CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA® | Press release | Business Wire | -2.25% | +2.53% | |
| Form 8-K OMEROS CORP For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | -0.51% | -1.96% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Omeros Corporation (OMER) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.11% | -2.02% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Omeros Corporation (OMER) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.10% | -0.57% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Omeros Corporation (OMER) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.29% | +1.84% | |
| Omeros Corporation (OMER) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.20% | -0.50% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Omeros Corporation (OMER) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.53% | -1.34% | |
| Omeros Corporation (OMER) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | +0.68% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Omeros Corporation (OMER) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.79% | +2.43% | |
| Form 8-K OMEROS CORP For: Jul 02 | SEC filing · Form 8-K | SEC EDGAR | +6.54% | +11.78% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Omeros Corporation (OMER) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +6.54% | +11.78% | |
| Omeros Corporation (OMER) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +6.54% | +11.78% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Omeros Corporation (OMER) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.43% | -0.21% | |
| Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA | Press release | Business Wire | +10.96% | +17.32% | |
| Form 8-K OMEROS CORP For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +1.23% | +1.04% | |
| Form 8-K OMEROS CORP For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -2.58% | +1.88% | |
| Omeros Announces Webcast Details for Annual Meeting of Shareholders | Press release | Business Wire | +5.67% | +5.78% | |
| Form 10-Q OMEROS CORP For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -9.51% | -9.78% | |
| Form 8-K OMEROS CORP For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -9.51% | -9.78% | |
| Omeros Corporation Reports First Quarter 2026 Financial Results | Press release | Business Wire | -9.51% | -9.78% | |
| Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026 | Press release | Business Wire | -0.69% | +1.93% | |
| Form ARS OMEROS CORP For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.07% | -0.81% | |
| Form DEF 14A OMEROS CORP For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | +0.07% | -0.81% | |
| CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug) | Press release | Business Wire | -2.00% | +0.48% | |
| Form 10-K OMEROS CORP For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +8.39% | +6.71% | |
| Form 8-K OMEROS CORP For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +8.39% | +6.71% | |
| Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results | Press release | Business Wire | +8.39% | +6.71% | |
| Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026 | Press release | Business Wire | -0.19% | -0.29% | |
| Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment | Press release | Business Wire | +0.80% | -4.99% | |
| Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program | Press release | Business Wire | +2.77% | +0.00% | |
| Omeros Announces First Commercial Sales of YARTEMLEA® | Press release | Business Wire | +0.95% | +9.89% | |
| Form 8-K OMEROS CORP For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | +6.20% | -7.05% | |
| Form 8-K OMEROS CORP For: Dec 24 | SEC filing · Form 8-K | SEC EDGAR | -3.04% | +8.51% | |
| Omeros Announces New Date for YARTEMLEA® Approval Conference Call | Press release | Business Wire | -3.04% | +8.51% | |
| FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA | Press release | Business Wire | +6.75% | -6.57% | |
| Form 8-K OMEROS CORP For: Nov 25 | SEC filing · Form 8-K | SEC EDGAR | +1.83% | -1.53% | |
| Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) | Press release | Business Wire | +1.83% | -1.53% | |
| Form S-3ASR OMEROS CORP | SEC filing · Form S-3ASR | SEC EDGAR | +3.54% | +18.52% | |
| Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025 | Press release | Business Wire | -0.45% | +4.24% | |
| Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group | Press release | Business Wire | +5.29% | +8.38% | |
| Form 8-K OMEROS CORP For: Oct 10 | SEC filing · Form 8-K | SEC EDGAR | -2.04% | -9.63% | |
| Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program | Press release | Business Wire | +0.36% | +3.62% | |
| Form 10-Q OMEROS CORP For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +4.25% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the OMER section they belong to.
Where else OMER is measured.
OMER earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Catalent, Inc. (CTLT) | 232 | +0.10% | 62% |
| Dyadic International, Inc. (DYAI) | 232 | 0.00% | 45% |
| SANUWAVE Health, Inc. (SNWV) | 232 | 0.00% | 49% |
| Bio-Rad Laboratories, Inc. Class A (BIO) | 231 | -0.06% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Omeros Corporation's median reaction calculated?
Every labeled OMER news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 232 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 57% of OMER's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does OMER's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.